BNP Paribas Financial Markets
PLX icon

BNP Paribas Financial Markets’s Protalix BioTherapeutics PLX Stock Holding History

BNP Paribas Financial Markets’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.5K Sell
12,664
-4,679
-27% -$9.91K ﹤0.01% 5129
2026
Q1 		$37.6K Buy
17,343
+322
+2% +$799 ﹤0.01% 4844
2025
Q4 		$30.6K Buy
17,021
+1,806
+12% +$3.69K ﹤0.01% 4902
2025
Q3 		$33.8K Buy
15,215
+8,498
+127% +$13.8K ﹤0.01% 4762
2025
Q2 		$9.94K Buy
6,717
+6,016
+858% +$12.3K ﹤0.01% 4843
2025
Q1 		$1.79K Sell
701
-15
-2% -$36 ﹤0.01% 4997
2024
Q4 		$1.35K Buy
+716
New +$1.01K ﹤0.01% 5052
2015
Q4 		– Sell
-6,177
Closed -$72.9K – 3623
2015
Q3 		$72.9K Sell
6,177
-1,105
-15% -$17.6K ﹤0.01% 2603
2015
Q2 		$142K Sell
7,282
-1,468
-17% -$30.5K ﹤0.01% 1894
2015
Q1 		$156K Sell
8,750
-3,406
-28% -$66.7K ﹤0.01% 1621
2014
Q4 		$224K Sell
12,156
-8,714
-42% -$187K ﹤0.01% 1332
2014
Q3 		$505K Buy
20,870
+8,100
+63% +$233K ﹤0.01% 1521
2014
Q2 		$466K Sell
12,770
-4,075
-24% -$164K ﹤0.01% 1516
2014
Q1 		$682K Buy
16,845
+795
+5% +$37.1K ﹤0.01% 1308
2013
Q4 		$624K Buy
16,050
+4,050
+34% +$171K ﹤0.01% 1193
2013
Q3 		$544K Buy
+12,000
New +$616K ﹤0.01% 1483

Other funds holding PLX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BNP Paribas Financial Markets's PLX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Protalix BioTherapeutics (PLX) stake by 27% in Q2 2026, selling an estimated $9.91K and leaving 12,664 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #5129.

BNP Paribas Financial Markets first reported a position in PLX in Q3 2013 and has held it in 16 quarters since. The position peaked at $682K in Q1 2014. 97 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

  • BNP Paribas Financial Markets held 12,664 shares of Protalix BioTherapeutics worth $29.5K as of Q2 2026.
  • BNP Paribas Financial Markets sold 4,679 Protalix BioTherapeutics shares in Q2 2026, an estimated $9.91K.
  • Protalix BioTherapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5129 holding.
  • BNP Paribas Financial Markets first reported a position in Protalix BioTherapeutics in Q3 2013 and has held it in 16 quarters since.
  • BNP Paribas Financial Markets's Protalix BioTherapeutics position peaked at $682K in Q1 2014.
  • 97 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.